AJMB  Vol.9 No.3 , July 2019
Diagnostic and Prognostic Value of Nuclear Factor Kappa-B in Diffuse Large B Cell Lymphoma in Egyptian Patients with Hepatitis C Virus Genotype 4
Abstract: Background: Members of the NFκB [p65] family have potential diagnostic and prognostic role in various inflammatory diseases and Lymphomas. Aim: We studied NFκB [p65] in paraffin blocks of hepatitis-C-virus [HCV] positive genotype-4 and HCV negative diffuse large B-cell lymphoma [DLBCL] patients, aiming at identification of its differential expression and prognosis in DLBCL and its subtypes; GCB and ABC. This is to establish its relation to HCV infection and its role in lymphogenesis. Besides assessing the role of new directly acting antiviral drugs [Sofusbuvir/Ledipasvir] concomitantly administered to [CHOP] combination in HCV positive DLBCL. Subjects and Methods: NFκB [p65] expression was assessed using Anti-NFκB [p65] antibody semi-quantitative technique in 30 newly diagnosed DLBCL patients [HCV positive [n = 15], HCV negative [n = 15]. Results: NFκB [p65] expression was higher in the HCV positive DLBCL patients than their HCV negative counterpart, with a positive correlation with the viral load [r = 0.536, p = 0.088]. NFκB [p65] expression was significantly more frequently detected in the ABC subtype than GCB subtype [p = 0.04]. Patients who expressed NFκB [p65] had higher incidence of extranodal involvement, advanced stages, higher LDH levels and IPI score. Besides, the expression of NFκB [P65] revealed an inferior overall response [OR] [p = 0.044]. Higher complete response rates to CHOP concomitantly with antiviral [ledipasvir/sofosbuvir] were encountered in the HCV positive group. In HCV positive group, NFκB [P65] displayed a positive relationship with the viral load and liver enzymes [p = 0.04], besides an inverse relation with serum albumin. This raises the possibility that NFκB [p65] expression is suggestive of the hepatic necro-inflammation in HCV patients. The ABC group presented more in advanced stages than GCB. Higher frequency of the ABC subgroup exhibited intermediate to high viral load, while it was less in the GCB. A statistically significant difference was found in the NFκB [p65] positive patients as regards MUM1 expression among the two groups [p ≤ 0.001]. Double positive [CD10+, MUM1+] and triple negative [CD10-, BCL6-, MUM1-] cases were encountered in the HCV positive group, and were characterized with a high NFκB [p65] expression. Conclusion: NFκB [p65] is expressed in patients with DLBCL, more frequently in ABC than in GCB subtypes. Expression of NFκB [p65] is associated with poor response to therapy in DLBCL. The NFκB [p65] disclosed an increased expression in HCV positive DLBCL compared to HCV negative group. The viral load displayed a positive correlation with the NFκB [p65] expression. Simultaneous administration of DAAs in combination with CHOP disclosed a better response and high tolerability.
Cite this paper: Halawani, N. , Sordi, M. , Aiad, M. , Sabaa, B. and Hashim, A. (2019) Diagnostic and Prognostic Value of Nuclear Factor Kappa-B in Diffuse Large B Cell Lymphoma in Egyptian Patients with Hepatitis C Virus Genotype 4. American Journal of Molecular Biology, 9, 121-143. doi: 10.4236/ajmb.2019.93010.

[1]   Zhang, B., Calado, D.P., Wang, Z., Frohler, S., Kochert, K., Qian, Y., et al. (2015) An Oncogenic Role for Alternative NF-κB Signaling in DLBCL Revealed upon Deregulated BCL6 Expression. Cell Reports, 11, 715-726.

[2]   Escárcega, R.O., Fuentes-Alexandro, S., García-Carrasco, M., Gatica, A. and Zamora, A. (2007) The Transcription Factor Nuclear Factor-Kappa B and Cancer. Clinical Oncology, 19, 154-161.

[3]   Perkins, N.D. (2007) Integrating Cell-Signalling Pathways with NF-κB and IKK Function. Nature Reviews Molecular Cell Biology, 8, 49-62.

[4]   Liu, T., Zhang, L., Joo, D. and Sun, S.-C. (2017) NF-κB Signaling in Inflammation. Signal Transduction and Targeted Therapy, 2, Article No. 17023.

[5]   Kasama, Y., Mizukami, T., Kusunoki, H., Peveling-Oberhag, J., Nishito, Y., Ozawa, M., et al. (2014) B-Cell-Intrinsic Hepatitis C Virus Expression Leads to B-Cell-Lymphomagenesis and Induction of NF-κB Signalling. PLoS ONE, 9, e91373.

[6]   Azzazi, M., Mohamed, M., Mousa, M., Mohammed, R. and Eldin Youssef, S. (2017) Multicentre Study of Hepatitis C Virus Status in Egyptian Patients with B-Cell Non-Hodgkin’s Lymphoma with Assessment of Patients’ Immunological State. The Egyptian Journal of Haematology, 42, 19-30.

[7]   Mele, A., Pulsoni, A., Bianco, E., Musto, P., Szklo, A., Sanpaolo, M.G., et al. (2003) Hepatitis C Virus and B-Cell Non-Hodgkin Lymphomas: An Italian Multicenter Case-Control Study. Blood, 102, 996-999.

[8]   Rajalakshmy, A.R., Malathi, J. and Madhavan, H.N. (2014) HCV Core and NS3 Proteins Mediate Toll Like Receptor Induced Innate Immune Response in Corneal Epithelium. Experimental Eye Research, 128, 117-128.

[9]   Dondelinger, Y., Aguileta, M.A., Goossens, V., Dubuisson, C., Grootjans, S., Dejardin, E., et al. (2013) RIPK3 Contributes to TNFR1-Mediated RIPK1 Kinase-Dependent Apoptosis in Conditions of cIAP1/2 Depletion or TAK1 Kinase Inhibition. Cell Death & Differentiation, 20, 1381-1392.

[10]   Torka, P., Hernandez-Ilizaliturri, F.J., Belliotti, S., Mavis, C., Gu, J. and Czuczman, M.S. (2014) Inhibition of Nuclear Factor Kappa B (NFκB)/Interferon Regulatory Factor 4 (IRF4) Signaling Pathway in Activated B-Cell (ABC) Diffuse Large B-Cell Lymphoma (DLBCL) by Combining MLN4924, a Novel NEDD8 Activating Enzyme Inhibitor (NAE) and Ibrutinib. Blood, 124, 1768.

[11]   Wang, J., Zhou, M., Zhang, Q.-G., Xu, J., Lin, T., Zhou, R.-F., et al. (2017) Prognostic Value of Expression of Nuclear Factor Kappa-B/p65 in Non-GCB DLBCL Patients. Oncotarget, 8, 9708-9716.

[12]   Schneider, C., Pasqualucci, L. and Dalla-Favera, R. (2011) Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma. Seminars in Diagnostic Pathology, 28, 167-177.

[13]   Mudaliar, M.A.V., Haggart, R.D., Miele, G., Sellar, G., Tan, K.A.L., Goodlad, J.R., et al. (2013) Comparative Gene Expression Profiling Identifies Common Molecular Signatures of NF-κB Activation in Canine and Human Diffuse Large B Cell Lymphoma (DLBCL). PLoS ONE, 8, e72591.

[14]   Peveling-Oberhag, J., Arcaini, L., Bankov, K., Zeuzem, S. and Herrmann, E. (2016) The Anti-Lymphoma Activity of Antiviral Therapy in HCV-Associated B-Cell Non-Hodgkin Lymphomas: A Meta-Analysis. Journal of Viral Hepatitis, 23, 536-544.

[15]   Swerdlow, S.H., Campo, E., Pileri, S.A., Harris, N.L., Stein, H., Siebert, R., et al. (2016) The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms. Blood, 127, 2375-2390.

[16]   Peveling-Oberhag, J., Arcaini, L., Hansmann, M.-L. and Zeuzem, S. (2013) Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas. Epidemiology, Molecular Signature and Clinical Management. Journal of Hepatology, 59, 169-177.

[17]   Kohli, A., Kapoor, R., Sims, Z., Nelson, A., Sidharthan, S., Lam, B., et al. (2015) Ledipasvir and Sofosbuvir for Hepatitis C Genotype 4: A Proof-of-Concept, Single-Centre, Open-Label Phase 2a Cohort Study. The Lancet Infectious Diseases, 15, 1049-1054.

[18]   Hans, C.P., Weisenburger, D.D., Greiner, T.C., Gascoyne, R.D., Delabie, J., Ott, G., et al. (2004) Confirmation of the Molecular Classification of Diffuse Large B-Cell Lymphoma by Immunohistochemistry Using a Tissue Microarray. Blood, 103, 275-282.

[19]   Parvatiyar, K., Barber, G.N. and Harhaj, E.W. (2010) TAX1BP1 and A20 Inhibit Antiviral Signaling by Targeting TBK1-IKKi Kinases. The Journal of Biological Chemistry, 285, 14999-15009.

[20]   Castro, I., Wright, J.A., Damdinsuren, B., Hoek, K.L., Carlesso, G., Shinners, N.P., et al. (2009) B Cell Receptor-Mediated Sustained c-Rel Activation Facilitates Late Transitional B Cell Survival through Control of B Cell Activating Factor Receptor and NF-κB2. The Journal of Immunology, 182, 7729-7737.

[21]   Foureau, D., Druhan, L.J., Steuerwald, N.M., Baxter, S.A., Fasan, O.O., Avalos, B.R., et al. (2015) Cytokine Profiling of ABC-Subtype and GCB-Subtype Diffuse Large B Cell Lymphoma: Systemic NFκB Activation and Impact on Myeloid-Derived Suppressor Cells Distribution. Blood, 126, 2666.

[22]   Hallas, C., Preukschas, M. and Tiemann, M. (2019) Immunohistochemical Distinction of ABC and GCB in Extranodal DLBCL Is Not Reflected in Mutation Patterns. Leukemia Research, 76, 107-111.

[23]   Foureau, D., Druhan, L.J., Steuerwald, N.M., Baxter, S.A., Fasan, O.O., Avalos, B.R. and Ghosh, N. (2015) Cytokine Profiling of ABC-Subtype and GCB-Subtype Diffuse Large B Cell Lymphoma: Systemic Nfkb Activation and Impact on Myeloid-Derived Suppressor Cells Distribution. Blood, 126, 2666.

[24]   Kloo, B., Nagel, D., Pfeifer, M., et al. (2010) C role of P Signaling for N Survival in a Subset of Activated B Diffuse Large B Lymphoma Cells. Proceedings of the National Academy of Sciences of the United States, 108, 272-277.

[25]   Merli, M., Visco, C., Spina, M., Luminari, S., Ferretti, V.V., Gotti, M., et al. (2014) Outcome Prediction of Diffuse Large B-Cell Lymphomas Associated with Hepatitis C Virus Infection: A Study on Behalf of the Fondazione Italiana Linfomi. Haematologica, 99, 489-496.

[26]   Magnano, L., Balague, O., Dlouhy, I., Rovira, J., Karube, K., Pinyol, M., et al. (2017) Clinicobiological Features and Prognostic Impact of Diffuse Large B-Cell Lymphoma Component in the Outcome of Patients with Previously Untreated Follicular Lymphoma. Annals of Oncology, 28, 2799-2805.

[27]   Besson, C., Canioni, D., Lepage, E., Pol, S., Morel, P., Lederlin, P., et al. (2006) Characteristics and Outcome of Diffuse Large B-Cell Lymphoma in Hepatitis C Virus-Positive Patients in LNH 93 and LNH 98 Groupe d’Etude des Lymphomes de l’Adulte Programs. Journal of Clinical Oncology, 24, 953-960.

[28]   Ennishi, D., Maeda, Y., Niitsu, N., Kojima, M., Izutsu, K., Takizawa, J., et al. (2010) Hepatic Toxicity and Prognosis in Hepatitis C Virus-Infected Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab-Containing Chemotherapy Regimens: A Japanese Multicenter Analysis. Blood, 116, 5119-5125.

[29]   Kloo, B., Nagel, D., Pfeifer, M., Grau, M., Duwel, M., Vincendeau, M., et al. (2011) Critical Role of PI3K Signaling for NF-κB-Dependent Survival in a Subset of Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Cells. Proceedings of the National Academy of Sciences of the United States of America, 108, 272-277.

[30]   El-Halawani, N., Nazir, A., Mashali, N., Sorour, A. and Moussa, M.A. (2017) The Diagnostic and Prognostic Impact of Serum miRNA-21 in a Sample of Hepatitis C/None Hepatitis Diffuse Large B Cell Lymphoma Egyptian Patients. American Journal of Molecular Biology, 7, 49-72.

[31]   Iannitto, E., Ammatuna, E., Tripodo, C., Marino, C., Calvaruso, G., Florena, A.M., et al. (2004) Long-Lasting Remission of Primary Hepatic Lymphoma and Hepatitis C Virus Infection Achieved by the α-Interferon Treatment. Journal of Hematology, 5, 530-533.

[32]   Musto, P., Dell’Olio, M., La Sala, A., Mantuano, S. and Cascavilla, N. (2005) Diffuse B-Large Cell Lymphomas (DBLCL) with Hepatitis-C Virus (HCV) Infection: Clinical Outcome and Preliminary Results of a Pilot Study Combining R-CHOP with Antiviral Therapy. Blood, 106, 2447.

[33]   Economides, M.P., Mahale, P., Kyvernitakis, A., Turturro, F., Kantarjian, H., Naing, A., Hosry, J., Shigle, T.L., Kaseb, A. and Torres, H. (2016) Concomitant Use of Direct-Acting Antivirals and Chemotherapy in Hepatitis C Virus-Infected Patients with Cancer. Alimentary Pharmacology & Therapeutics, 44, 1235-1241.